SCHEMBL17064941

SCHEMBL17064941

O=CC=CC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27034882 1.00
SCHEMBL17064940 1.00
SCHEMBL1504406 0.88
SCHEMBL27034791 0.88
SCHEMBL3007557 0.88
SCHEMBL17038126 0.87
SCHEMBL18965879 0.85 ADH1A (0.35)
SCHEMBL8893323 0.85 ADH1A (0.35)
SCHEMBL7869549 0.85 ADH1A (0.35)
SCHEMBL7114170 0.85 ADH1A (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117466815-A Synthesis method of azaanthrone compound 西北工业大学 2024-01-30 CN disclosed
EP-3113772-A1 HUMAN PLASMA KALLIKREIN INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2017-01-11 EP disclosed
WO-2015134998-A1 HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2015-09-11 WO disclosed